findmyKOL
Clinical trialNCT05097209UnknownPhase 2Interventional

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

SponsorWei JiangEnrollment200Nasopharyngeal Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Guangxi Nanxishan Hospital

    Guilin, Guangxi, China

    Recruiting
  • Guilin Medical University

    Guilin, Guangxi, China

    Recruiting
  • Laibin People'S Hospital

    Laibin, Guangxi, China

    Recruiting
  • Linshan People'S Hospital

    Linshan, Guangxi, China

    Recruiting
  • Wuzhou Red Cross Hospital

    Wuzhou, Guangxi, China

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Apr 2022
Primary completion
6 Apr 2025
Completion
6 Apr 2026
Last update posted
23 Mar 2023
Registered enrollment
200
Registry id
NCT05097209
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.